| 09:00–10:30 |
Parallel Workshops
From Biomarkers to Companion Diagnostics: The Emergence of Personalized Medicine in Clinical Development and Oncology Dealmaking
For the past several years, biomarkers and personalized medicine approaches have become increasingly important throughout the drug discovery and development pipeline in oncology, but only recently have we perhaps passed the tipping point where biomarker strategies have crossed over from “nice to have” to “must have” components of a drug development strategy.
In this workshop, experienced biologists, dealmakers, and biotechnology executives will explore:
- Recent applications of personalized medicine strategies to advance clinical development of novel therapeutics
- Predicting a changing regulatory environment and its impact on translating biomarkers to the clinic and into the marketplace
- The challenges of implementing personalized medicine strategies in a clinical setting
- The value of meeting these challenges in terms of speed and value of securing your licensing deal
This session will be structured with multiple Q&A breaks to ensure an informative and dynamic exchange.
Moderator:
John Freshley – CBO, Compendia Bioscience
Panelists:
- Christian Meisel – Oncology Site Leader and Site Head Translational Medicine,
Roche
- Joe Monforte – Executive VP and CSO, Althea Diagnostics
- Linda Pullan – President, Pullan Consulting
- Cecilia Schott – Business Development Director, Personalised Healthcare, AstraZeneca
How does Corporate Strategy and Positioning of Assets Affect a Company’s Dealmaking?
Companies often have trouble strategically positioning themselves and their assets within the marketplace. This may not only have negative effects on their ability to monetize assets and their legal position, it can also make the company less attractive to a potential investor or deal partner.
While a solid strategic business plan with the right ingredients can set forth a recipe for success, often companies don’t sit down and define what purpose such a plan serves, what it should contain and what role it plays in deals and in negotiations. This workshop will examine key concepts of these strategic documents and how to:
- Describe the company’s strategy most attractively to potential partners
- Anticipate key issues in a deal and account for them early on in the strategic plan
- Define interim and long term objectives as well as goals and target dates for the company
- Address intellectual property issues
- Manage the clinical trial and regulatory process
Executives who have experience with different business models will discuss how formulating the corporate strategy in a comprehensive business plan can provide a roadmap to success.
Moderator:
Diane Romza Kutz – Partner, Troutman Sanders
Panelists:
- Graham Bush – Executive Director, Global Commercial Development, Amgen
- Gerard Kennealey – VP, Business Development, Cephalon
- Michael McCullar – Senior VP, Strategy and Discovery Operations, SuperGen
- Chris Piggott – CBO, Biotie Therapies Corporation
- Andrew Thompson – VP, Commercial Operations, Eurand
CMO-Biotech Partnerships: Evaluating Different Business Models
Financing of biopharmaceutical process development as 'fee for service' is a major challenge for most biotechs. More and more CMOs offer alternative business models such as mix of fee for service with project specific investment or reduced fees in combination with technology licenses or option on later licensing rights.
But what should you consider when a partnership with a CMO goes beyond the conventional way? Opportunity or trap?
The panel will discuss the characteristics of the individual models, the risks and benefits and will clarify the questions you always wanted to ask.
Moderator:
Klaus Binder – Managing Director and Founder, Binder Associates
Panelists:
- Jochen Alberstetter – VP, Project Management and Supply Chain Management,
Vetter Pharma-Fertigung GmbH & Co. KG
- Uwe Bücheler – Senior VP, Biopharma Operations, Boehringer Ingelheim, Germany
- Fritjof Linz – Senior Director, Business Development and Marketing, DSM Biologics
- Klaus B. Schoepe – Senior VP, Client Relations, Rentschler Biotechnologie
- Frank Ubags – CFO, Scil Proteins
- Thomas Wellner – CEO and President, Therapure Biopharma
The Perfect Pitch: BIO-Europe’s Got Talent!
Win a one-to-one meeting with senior executives from big pharma. Each member of the audience will have 30 seconds to present their company or technology to a star-studded panel of pharma BD executives. Eight lucky individuals will be selected to go to a second round that includes a one-minute presentation followed by 3–4 minutes of Q&A and feedback with the panel. Winners will be selected for follow-up meetings with one or more of the panelists.
Audience preparation notes:
- Participants will be required to state their name, title and company
- Participants will be judged on 1) Quality of the overall pitch; 2) Relevance to the panelists
- Remember, the primary goal of an elevator pitch is to get a follow-up meeting
- Pre-workshop coaching is available from the Moderator (contact: doug@macbiocom.com)
- Practice, practice, practice
Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications
Panelists:
- Lubor Gaal – Executive Director, Strategic Transactions Group, Bristol-Myers Squibb
- Claudia Karnbach – Senior Director, Business Development and Licensing, Oncology, Bayer HealthCare Pharmaceuticals
- Robert J. Wills – VP, Alliance Management,
Johnson & Johnson Pharmaceutical Services
Judges:
- Margaret Beer – Merck & Co., Inc.
- Veronique Bouchet – AstraZeneca
- Rick Cousins – GlaxoSmithKline
- Nora Dyer – Novartis
- Fran Heller – Exelixis
- Tomas Landh – Novo Nordisk
- Michael Motz – Roche
- Stephen Schleier – Pfizer
Partnering Landscape in China
As the preeminent emerging BRIC market, the buzz around partnering in China is building. China's rapidly growing drug market has become an essential focus for big pharma and biotech companies, and global collaborations already exist in R&D, manufacturing, commercialization as well as after sale services. Many overseas life science companies have started initiatives to increase their market share in China, and Chinese companies are developing new strategies for the domestic as well as international markets. Our panel of experts will address, from their personal and company perspectives, various aspects of how and why China is evolving so rapidly and what they see as key drivers for favorable partnering models as well as the challenges in such collaborations between Western and Chinese companies.
Moderator:
Alicia Hong – Head of China Practice, WilmerHale
Panelists:
- Michael Heerde – Director, Strategy and Business Development, Bayer HealthCare China
- Ruediger Herrmann – Partner, WilmerHale
- Joachim Seipelt – VP Cooperations, AVIR Green Hills Biotechnology
- Victor Shi – President, Asia Pacific, QIAGEN
|
| 13:30–18:15 |
Parallel Panel Discussions
| Business Development Track |
| 13:30–14:30 |
Is Corporate Venture Replacing Traditional Venture Capital?
As a consequence of the global financial crisis, VC financing for biotech companies has suffered significantly both in total volume and in the number of financing rounds.
To escape a major consolidation, the biotech sector has adapted its business models towards more cash-generating service models and particularly towards partnering with big pharma.
Pharma, on the other hand is under pressure to transform its operational model including ensuring better access to innovation and improving R&D productivity. Partnering with biotech, and especially around early stage developments and technology platforms necessitated new financing instruments beyond existing funds allocated for M&A and product alliances. In this context, corporate venture funds were redirected to be used much more strategically to pursue and ensure access to innovation.
The panel will explore in more detail how corporate venture funds are positioned and structured in order to manage their dual role as investors and consortial partners together with VC players, as well as dealmakers to capture innovative developments and strategic assets for their parent companies. In addition, activities of corporate venture funds are also viewed from the perspective of a funded company.
Moderator:
Siegfried Bialojan
– Executive Director, Head European Life Science Center Mannheim, Ernst & Young
Panelists:
- Roel Bulthuis – Head of Merck Serono Ventures
- Markus Goebel – Managing Director,
Novartis Venture Funds
- Sven Rohmann MD, PhD – Venture Partner and Managing Partner Europe, Burrill & Company
- Ed Torres – Managing Director, Lilly Ventures
- Christian Zahnd – CEO, Molecular Partners
|
| 14:45–15:45 |
The Pendulum Swings: A Look Back at 2010 and Prospects for the Year Ahead
Earlier this year, the results of the Campbell Alliance Dealmakers’ Intentions Survey demonstrated an ongoing interest in late stage post-proof-of-concept assets amongst large pharma and biotech companies. In theory, this strategy of bringing in near market-ready assets would help replace lost revenue related to a loss of patent exclusivity and help fill any relevant pipeline gaps. Unfortunately, after two years of competitive in-licensing, many late stage assets have been well picked over, leaving large companies with stuffed Phase II pipelines and a commitment of significant funds to commercialize Phase III assets in the next few years.
In classic form, the pendulum has swung back. Around mid-year, many larger companies began to turn their attention back toward in-licensing early stage assets. Dealmaking interest has centered around assets that have well understood mechanisms of action or that address well understood disease pathways—particularly in oncology, CNS, and a few other specialty areas. Competition for those assets is getting tough across all stages of development and any large companies that want to compete must be prepared to look at earlier stage assets. This interest is resulting in expensive early stage deals, including some with USD 40–60 million upfront, which is remarkable considering the products won’t be on the market for 8–10 years.
What does this change in the dealmaking landscape mean for both large and emerging companies for the remainder of the year? Will this level of competition continue into 2011?
Join us for this interactive discussion as the team reviews licensing trends thus far for 2010, examines two deals that are indicative of this year’s landscape, and discuss prospects for the year to come.
Moderator:
Ben Bonifant – Senior VP and Practice Area Leader, Campbell Alliance
Panelists:
- Frank Borriello – Director, Corporate Development,
Millennium: The Takeda Oncology Company
- Susanne Kreutz – Director, GBD&L-OT, Licensing Drug Discovery, Bayer Schering Pharma AG
- Sunil Patel – Senior VP, Corporate Development, OncoMed Pharmaceuticals
- Shannon Thomas – Associate Director, Business Development, Seattle Genetics
|
| 16:00–17:00 |
The $100 Million Deal
Licensing and acquisition transactions between pharmaceutical companies and smaller biotechs usually include upfront (often about $100 million), milestone and royalty payments. In an effort to align risk with reward, pharma has been pushing for smaller upfront payments and a series of milestones if performance targets are met. For many cash strapped biotech companies, these deals are bittersweet, as they give them an opportunity to further the development of their pipeline, but don’t necessarily satisfy their investors.
A panel of different stakeholders, including venture, pharma and biotech, will discuss what these back loaded deal structures mean for them. They will consider what factors influence deal structures (such as the absence of an IPO alternative, regional deals and competitive processes), and how biotech companies should be built if structured transactions continue to be prevalent in the future.
Moderator:
Stuart Collinson – Partner, Forward Ventures
Panelists:
- Keith Bryant – Director, Corporate Development, Arena Pharmaceuticals
- Mercedes Diz – Associate Director, Licensing and Corporate Development, Almirall
- David Phillips – Partner, SR One, the corporate venture capital arm of GlaxoSmithKline
- Barbara Yanni – VP and Chief Licensing Officer,
Merck & Co., Inc.
|
| 17:15–18:15 |
Business Models that Work
Biotech companies have tried many business models over the last two decades, but only a few of these lead to the creation of sustainable businesses. A group of seasoned veterans from the corporate and venture worlds talk about what works and what doesn't work, what models are appropriate for different kinds of projects, and how the financial crisis has changed their plans.
The panel will also look at new strategies for drug development from precompetitive work and translational science, to incubator-like spaces being set up by big pharma and different collaboration models among industry players, all the way up to changing models on the marketing end.
Moderator:
Karen Bernstein – Co-founder, Chairman and Editor-in-chief, BioCentury
Panelists:
- Francesco De Rubertis – Partner,
Index Ventures / Index Seed
- Tim Edwards – CEO, Cellzome
- Simon Moroney – CEO, MorphoSys
- Edwin Moses – CEO and Chairman, Ablynx
- Onno van de Stolpe – CEO, Galapagos
|
| Spotlight Track |
| 13:30–14:30 |
Biotech Innovation and Access to Capital in an Era of Reform
Since the global economic crisis began, governments have proposed and enacted financial and healthcare policies that impact—positively and negatively—biotech companies, as well as availability of capital to fund biotechnology innovation. Efforts to cut national health care costs in the USA and Europe, in particular the German healthcare reform (Gesundheitsreform), have a cost to companies in terms of new approvals and reimbursement rates. Further, new American and European financial laws, and associated regulations have added to an already uncertain environment for investors, reducing their appetite for risk.
Yet, lawmakers around the globe are also enacting policies to seed small businesses and generate jobs—many of which will have direct and indirect financial impacts on biotech companies and investors. In the USA alone, USD 1 Billion is being provided to small biotech companies to fund therapeutic research and development. In the EU, public-private partnerships to promote and fund biotech R&D are being seriously considered. In this complex environment, it is more important than ever to have the right policy mix that encourages capital formation. This panel will discuss how these recently enacted and pending policies are viewed by the biotech and life science investor community and the likely short term, long term and cumulative impact on the industry.
Moderator:
Alan Eisenberg – Executive VP, Emerging Companies and Business Development, Biotechnology Industry Organization (BIO)
Panelists:
- Gary L. Geipel – Director, Corporate Affairs, Lilly Deutschland
- Paul Hastings – President and CEO,
OncoMed Pharmaceuticals
- Vaughn Kailian – Managing Director, MPM Capital
- Gordon McCauley – President and CEO, Allon Therapeutics
|
| 14:45–15:45 |
The Diabetes Dealmaking Dilemma
Could diabetes drug development be headed for troubled waters? While the cost of clinical trials required for regulatory approval may be dissuading biotechs from entering this therapeutic area, there are also a number of late stage opportunities that seem unable to attract partners. And with established drugs subjected to new restrictions, what is needed to support continued innovation for diabetes drug development? How can low levels of innovation be avoided? What will it take to secure a partner?
Expert panelists will explore the reasons for a decreasing level of innovation in the diabetes space, and the partnering potential for existing treatment candidates. They will also discuss possible new sources of innovation for diabetes treatment as well as if and how existing hurdles to partnering success can be overcome.
Moderator:
Ed Mathers – Partner, New Enterprise Associates
Panelists:
- Finn Benned Hansen – Corporate VP, Diabetes Strategy and Sourcing, Novo Nordisk
- Lionel Carnot – Partner, Bay City Capital
- Robert Knowles – Senior Director, Worldwide Business Development, Pfizer
- Chuck McWherter – Senior VP, Research and Preclinical Development, Metabolex
|
| 16:00–17:00 |
The Future of Diagnostics' Partnering Strategy
Much has been said (not only at this conference) regarding the evolving role biomarkers and companion diagnostics have within drug development and therapeutic treatment. One aspect that is still to be examined is how personalized medicine and companion diagnostics will be integrated within comparative effectiveness research (CER), especially as European regulatory bodies seem to be embracing CER as the most efficient means to determine the best treatment for patients. Soaring healthcare costs have lead to the evolution of pharmacies that have resorted to diagnostic testing to enable selection of generics over more expensive branded drugs. Health IT companies are emerging stakeholders that are looking to drive personalized medicine by standardizing practice and streamlining treatment decisions.
As this situation evolves, how will diagnostic companies and their pharma partners be affected by this new regulatory atmosphere? How will the increasing demands for CER change the roles that regulators and payors have traditionally had in the drug development model and how will they affect the treatment that is ultimately provided for patients? How will new stakeholders such as pharmacies and health IT companies change the personalized medicine landscape? How will the lean healthcare philosophy change the treatment paradigm and patient outcomes?
Moderator:
Anne Bruinvels – CEO, Elixior and Executive Director, EPEMED
Panelists:
- Harry Glorikian – Managing Partner,
Scientia Advisors
- Peter Homberg – Partner,
Raupach & Wollert-Elmendorff
- Richard Watts – Director, Pharma Business Development, Qiagen
- Ruediger Weseloh – Senior Director, Head Negotiations, Merck Serono
|
| 17:15–18:15 |
The Soft Money Fountain: Creating an Overhang of Start-up Companies?
There is a growing trend in public and private funding towards seed and very early stage funding. The recent revival of corporate venture funds, tax incentive schemes supporting small start-ups, public grants and subsidies to get companies off the ground in record numbers: despite (or because of) the crisis there is a quickly increasing number of sources that young companies can look to for initial funding up to an A-Round.
What are the different forces and influences that shape the European early stage market for innovative biotechs? What are the reasons for the new fashion in early stage funding? And importantly, what will the implications be once companies outgrow these sources, both for the companies themselves and the biotech investment climate in general? Are we moving towards a precipice of mid-stage collapses in an already stretched capital market or will seed investors be saved by big pharma in the end?
Moderator:
Christian Schneider – Managing Partner, Vesalius Biocapital
Panelists:
- Michael Brandkamp – Co-CEO,
High Tech Gruenderfonds
- John Shields – Principal, Science and Technology, Abingworth
- Klaus Stoeckemann – Managing Partner,
Peppermint Management
- Raphael Wisniewski – Partner,
Edmond de Rothschild Investment Partners
|
| International Seminars |
| 13:30–14:15 |
Australia
Australian biotechnology
The country seminar will cover the following topics:
- Industry overview—areas of strengths and capabilities for research and commercialization, including clinical trials; regional distribution and employment figures
- Business climate—financial infrastructure; government support; licencing and investment activities; commercialization activities
- Regulatory environment—TGA registration; international agreements for the registration of therapeutic goods; protection of intellectual property
Australia is the leading center for biotechnology in the Asia-Pacific region with almost 450 biotechnology companies and 600 medical technology companies, the majority in human therapeutics. It is home to numerous world-class medical research organizations, co-operative research centers, excellent clinical research organizations and multinational pharma in Australian offices and/or facilities.
The Australian and State and Territories Governments encourage investment in this sector and offer a range of programs to support R&D, collaboration with international companies and commercialization.
Australia offers world-class science, capacity for international partnerships, cost effectiveness, and a robust, transparent and efficient regulatory system, in particular surrounding intellectual property.
Australia is one of the most open, stable and reliable economies in the world. The Australian economy was ranked most resilient in the world for six of the last eight years and has sustained a strong growth rate of 3.4 percent from 1998–2009. Australia was the only advanced economy to record positive growth in 2009.
Australia’s open social and political culture, advanced education system and investment in research encourage innovation and inventiveness.
Visit www.austrade.gov.au
Speaker:
Roseline Yardin – Senior Industry Adviser, ICT, Health and Biotechnology, Australian Trade Commission
|
| 14:30–15:15 |
Italy
Speakers and Content:
14:30–14:32
Opening remarks
Ines Aronadio – Trade Commissioner, Italian Trade Commission of Berlin
14:32–14:45
Overview of Italian Biotech sector
Leonardo Vingiani – Director, Assobiotec
Presentation of BioinItaly Report 2010
14:45–14:58
Italian research center and scientific park network
Ines Aronadio – Trade Commissioner, Italian Trade Commission of Berlin
The promotion of Italian excellence areas
14:58–15:11
The Italian BioParks project
Francesco Maria Senatore – Coordinator, Italian Bioparks
15:11–15:15
Q&A and conclusions
|
| 15:30–16:15 |
Canada (Québec)
Business Opportunities in Québec
Learn about Québec's most promising companies, technologies and development partners, as well as how you can advance your organization’s competitiveness by capitalizing on Québec’s strengths. As home to Canada’s largest innovation cluster, Québec is a nucleus of creative thinking, development and discovery in the life sciences with over 750 organizations employing 50,000 people, 20 university hospitals and close to one third of all beds for Phase I clinical studies in North America.
You will understand why major pharmaceutical firms, contract research organizations and biotechnology companies have chosen to establish themselves in Québec. Furthermore, you will learn about the Québec way of doing business, the province’s main players, and growth areas in which you can develop partnerships.
Québec is a great place to do business, since it offers:
- An integrated biopharma hub, from basic research to clinical trials and commercialization
- Easy access to the North American market
- State-of-the-art scientific expertise
- A highly skilled workforce
- A wide range of companies looking for partnerships and technologies
Speakers:
- Francis Beaulieu – Director, Business Development and Strategic Partneships,
Montréal InVivo (a founding partner of BiopolisQuébec)
- Josée Blanchard – Director, Corporate Development, Sherbrooke Innopole
|
| 16:30–17:15 |
Israel (BioJerusalem)
Innovation in Jerusalem
Jerusalem is home to world renowned academic, medical and research institutions as well as a vibrant biomedical industry, all supported by a diverse human capital of highly educated and talented professionals, a state-of-the-art biomedical infrastructure and a highly entrepreneurial spirit.
Jerusalem's numerous “BioStrengths” include:
- A world-class knowledge base and climate of innovation, which is rooted in Jerusalem's leading research and medical institutions, including the Hebrew University of Jerusalem, Hadassah Hospital and Shaare Zedek Medical Center.
- A valuable pool of biotech, medical device and pharma companies. The region is home to 130 life science companies including Teva, Medinol, Sigma Aldrich, Rafa Laboratories, Brainsway, as well as many promising start-ups.
- A unique biomedical R&D infrastructure rich in modern R&D facilities and technology parks, including the new BioMed Park at Ein Kerem and Israel's biotech incubator, Bioline Innovations Jerusalem.
- Generous financial incentive packages. Jerusalem is the only centrally located city in Israel to enjoy National Development Zone A status entitling companies to the best grants and tax incentives available in Israel today, as well as municipal incentives offered by the Jerusalem Development Authority.
- Dynamic tech transfer activity by local technology transfer organizations. Yissum’s (Hebrew University of Jerusalem) revenues from life science products place it among the top 15 technology transfer companies worldwide. Hadasit (Hadassah Medical Organization) is a powerhouse of start-up activity.
- A highly skilled professional workforce. The area boasts the highest number of Israel's life science PhD students, over 2,000 leading scientists and physicians, and 3,100 employees in the life science industry.
Program and speakers:
An Overview of the Jerusalem BioMed Cluster
Chen Levin – Executive Director BioJerusalem, The Jerusalem Development Authority
Israel's Biotechnology Incubator
Nir Gamliel – VP Business Development, BioLineRx
Technology Transfer at the Hebrew University
Shoshi Keynan – VP Licensing, Pharmaceuticals, Yissum
|
| 17:30–18:15 |
Austria
From Science to Business in Austria
Generating added value for biopharmaceutical manufacturing
This workshop focuses on examples of turning ideas, science and technologies into innovations valuable for commercial protein manufacturing, presented by speakers from academia and industry.
Two Austrian companies, VTU Technology and Boehringer Ingelheim RCV have only recently started a collaboration to advance an existing technology platform and they will show intriguing results from a joint project that was developed for commercial use in contract manufacturing. Both companies successfully cooperate with universities, one example, the cooperation with the Austrian Centre of Industrial Biotechnology will be presented.
The presented approaches prove that bundling expertise from different sources creates a competitive advantage for the company´s customers by speeding up time to market.
Moderator:
Johannes Sarx – LISA Vienna Region
Panelists:
- Monika Henninger-Erber – Boehringer Ingelheim RCV GmbH & Co KG
- Alois Jungbauer – Austrian Centre of Industrial Biotechnology
- Thomas Purkarthofer – VTU Technology GmbH
|
|
Big Pharma Presentations ► |
| 13:30–13:45 |
Boehringer Ingelheim Licensing |
| 13:45–14:00 |
Boehringer Ingelheim Biopharmaceuticals |
| 14:00–14:20 |
Bayer Schering Pharma AG |
| 14:20–14:40 |
sanofi-aventis |
| 14:40–15:00 |
Novartis |
| 15:00–15:20 |
Abbott |
| 15:20–15:40 |
Merck Serono |
| 15:40–16:00 |
AstraZeneca |
| 16:00–16:20 |
Merck & Co., Inc. |
| 16:20–16:40 |
Novo Nordisk |
| 16:40–17:00 |
Baxter |
| 17:00–17:20 |
Roche |
| 17:20–17:40 |
Pfizer |
| 17:40–18:00 |
Bristol-Myers Squibb |
|
13:30–18:30
One-to-one Meetings ►
|
Through Munich to the Heart of Biotech
The guided tour has reached capacity and registration is closed.
Welcome Recepetion Location:
Evening Reception Location:
Evening Reception Location:
